Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major economic or geopolitical headlines in the past hour, leaving markets largely unmoved.
  • Trading volumes declined as investors awaited upcoming data releases and central bank cues.
  • Currencies, oil, and Treasury yields showed minimal movement without fresh market catalysts.
  • Corporate news was sparse with no significant earnings, M&A, or guidance revisions reported.
  • Political calendars produced no new policy announcements likely to affect markets in the near term.

Latest Articles

ASP Isotopes Inc. Announces that Renergen Limited’s Subsidiary has Entered into a Take-or-Pay Contract for the Supply of Liquified Natural Gas to Be Produced at the Virginia Gas Project in South Africa
Aug 6, 2026
Avery Klein
Press Releases

ASP Isotopes Inc. Announces that Renergen Limited’s Subsidiary has Entered into a Take-or-Pay Contract for the Supply of Liquified Natural Gas to Be Produced at the Virginia Gas Project in South Africa

ASP Isotopes Inc. announced that its subsidiary Renergen's subsidiary, Tetra4, has entered a five-year take-or-pay contract to supply liquified natural gas (LNG) to a South African food processor. This contract supports Phase 1 of the Virginia Gas Project, targeting commercial production in Q3 2026, with approximately 75% of Phase 1 LNG volumes now…

ASPI
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Aug 6, 2026
Marcus Reed
Press Releases

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Praxis Precision Medicines announced positive mid-cycle FDA meetings for its drug candidates ulixacaltamide and relutrigine, with no major safety or efficacy concerns and no advisory committee meetings planned. The company is accelerating commercial preparations for potential approvals in essential tremor and developmental epileptic encephalopathie…

PRAX
Globalstar Announces Second Quarter 2026 Financial Results
Aug 6, 2026
Leila Farooq
Press Releases

Globalstar Announces Second Quarter 2026 Financial Results

Globalstar, Inc. reported its second quarter 2026 financial results, generating $64.8 million in revenue with record high Commercial IoT subscriber activations. The company continues regulatory progress on its merger agreement with Amazon and is advancing next-generation satellite constellation initiatives. Despite revenue growth in some segments, …

GSAT
Freshworks to Participate in Oppenheimer 29th Annual Technology, Internet & Communications Conference
Aug 6, 2026
Sofia Navarro
Press Releases

Freshworks to Participate in Oppenheimer 29th Annual Technology, Internet & Communications Conference

Freshworks Inc. announced that COO and CFO Tyler Sloat will participate in a fireside chat at the Oppenheimer 29th Annual Technology, Internet & Communications Conference. The session is set for August 12, 2026, with an audio replay available on Freshworks' investor relations site. The company is positioned as an AI-powered unified service operatio…

FRSH
Nano-X Imaging Ltd. Announces Pricing of a $8 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Aug 6, 2026
Leila Farooq
Press Releases

Nano-X Imaging Ltd. Announces Pricing of a $8 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Nano-X Imaging Ltd., a Nasdaq-listed medical imaging technology company, has priced an $8 million registered direct offering with a single long-term institutional investor. The offering consists of 8 million ordinary shares and warrants exercisable at $1.15 per share. Proceeds will be used for working capital and general corporate purposes. The com…

NNOX
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
Aug 6, 2026
Derek Hwang
Press Releases

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

MIRA Pharmaceuticals announced positive toxicokinetic data from a 7-day repeated-dose study of their obesity treatment candidate SKNY-1 in Beagle dogs. The drug showed dose-dependent systemic exposure and rapid absorption, de-risking dose selection and supporting advancement into GLP toxicology studies and IND-enabling development. SKNY-1 aims to t…

MIRA
Exyn Nexys Selected by Leading U.S. Government Research Organization Following Head-to-Head Evaluation Against Commercial LiDAR System
Aug 6, 2026
Jordan Park
Press Releases

Exyn Nexys Selected by Leading U.S. Government Research Organization Following Head-to-Head Evaluation Against Commercial LiDAR System

Exyn Technologies announced that its Exyn Nexys handheld LiDAR scanner has been chosen by a leading U.S. government research and engineering organization following a rigorous head-to-head assessment against other commercial LiDAR systems. The device was selected due to its survey-grade accuracy, mobility, and speed, and will be used for creating de…

EXYN
Tejon Ranch Company Announces Second Quarter 2026 Financial Results
Aug 6, 2026
Ajmal Hussain
Press Releases

Tejon Ranch Company Announces Second Quarter 2026 Financial Results

Tejon Ranch Co. announced its second quarter 2026 financial results, reporting net income attributable to common stockholders increased by $4.3 million to $2.6 million compared to a loss in the prior year. Revenues rose $6.3 million to $17.4 million driven by land sales and growth in multifamily, mineral resources, and ranch operations segments. Th…

TRC
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Aug 6, 2026
Marcus Reed
Press Releases

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical announced full enrollment and successful dosing of all 20 participants in its Phase 1 SLIM-1 trial evaluating NPM-139, a miniature subdermal semaglutide implant designed for ultra long-acting delivery over 6 to 12 months. The trial is assessing safety, tolerability, and pharmacokinetics compared to Wegovy injections, with topline dat…

VANI
Aemetis Reports Second Quarter 2026 Financial Results
Aug 6, 2026
Nina Shah
Press Releases

Aemetis Reports Second Quarter 2026 Financial Results

Aemetis, Inc. announced strong financial results for Q2 2026 with revenues increasing 20% year-over-year to $62.7 million driven by growth in California Ethanol and Dairy Renewable Natural Gas segments. The company reported positive operating income of $5.8 million, a turnaround from an operating loss in the prior year period, supported by $8.6 mil…

AMTX
Safe Harbor's Cannabis-Focused 401(k) Plan Gains Early Adoption as Canopy HR Names It the Recommended Retirement Solution for its Clients
Aug 6, 2026
Hana Yamamoto
Press Releases

Safe Harbor's Cannabis-Focused 401(k) Plan Gains Early Adoption as Canopy HR Names It the Recommended Retirement Solution for its Clients

SHF Holdings, Inc. (Safe Harbor) announced that Canopy HR has selected Safe Harbor's Multiple Employer 401(k) Plan as the recommended retirement solution for its cannabis industry clients. Since its launch in April 2026, the plan has onboarded six new cannabis businesses, including a multistate operator, demonstrating strong early market adoption. …

SHFS
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Aug 6, 2026
Derek Hwang
Press Releases

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Theriva Biologics has dosed the first patient in its VIRAGE2 Phase 2a trial, aiming to evaluate more frequent dosing of its oncolytic virus therapy, VCN-01, in combination with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC). Building upon encouraging Phase 2b data, this exploratory study seeks to refine dosing regimens…

TOVX
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
Aug 6, 2026
Jordan Park
Press Releases

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Ascendis Pharma announced positive data from its Phase 2 COACH trial combining TransCon CNP and TransCon hGH, showing sustained, unprecedented growth in children with achondroplasia through Week 78. Additionally, the pivotal ApproaCH trial demonstrated durable benefits from TransCon CNP monotherapy over two years. The company also reported signific…

ASND